Amundi Apellis Pharmaceuticals, Inc. Transaction History

Amundi

$276 Billion
Q2 2025

A detailed history of Amundi transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Amundi holds 1,604,105 shares of APLS stock, worth $37.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,604,105

Previous 329,582 386.71%

Holding current value

$37.1 Million

Previous $7.21 Million 285.28%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$16.36 - $23.0 $20.9 Million - $29.3 Million	1,274,523 Added 386.71%	1,604,105 $27.8 Million
Q4 2024 Feb 07, 2025	BUY	$26.18 - $35.42 $8.55 Million - $11.6 Million	326,604 Added 10967.23%	329,582 $10.5 Million
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $85,885 - $122,544	2,978 New	2,978 $85,000
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $393,933 - $515,406	7,112 Added 2.95%	248,483 $14.6 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $1.4 Million - $2.44 Million	-37,593 Reduced 13.48%	241,371 $14.4 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $5.74 Million - $21.7 Million	242,860 Added 672.67%	278,964 $10.6 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $58,966 - $71,755	-769 Reduced 2.09%	36,104 $3.29 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $514,120 - $738,903	11,035 Added 42.71%	36,873 $2.43 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $197,606 - $278,952	-4,570 Reduced 15.03%	25,838 $1.34 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $1.19 Million - $1.84 Million	26,485 Added 675.12%	30,408 $1.75 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $160,450 - $254,602	3,923 New	3,923 $248,000

Others Institutions Holding APLS

# of Institutions

295

Shares Held

132M

Call Options Held

2.97M

Put Options Held

623K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.54B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account